Combinations of HDAC inhibitors with DNMT inhibitors show superior ER re‐expression in breast cancer cell lines, and testing of the HDAC inhibitor entinostat + exemestane is ongoing in HR+ breast cancer patients (NCT02115282; Yang et al, 2000; Connolly & Stearns, 2012). This evidence concerns the gene ESR1 and breast carcinoma.